Respiratory Syncytial Virus (RSV)

View the comprehensive RSV toolkit. This resource provides in depth guidance on immunization, testing, diagnosis and patient care related to RSV. A snapshot of RSV guidance can be found below.

Immunization

• The following criteria from the American Academy of Pediatrics (AAP) Nirsevimab Implementation Guide may help your practice identify eligible patients to receive Beyfortus. The AAP Beyfortus/Nirsevimab criteria includes:
• Infants born shortly before or during RSV season (October through March).
• Consider whether any of these infants have a parent who was eligible to receive the maternal RSV vaccine. Make sure to flag these for parental follow-up in your EHR.
• Infants born earlier that year who will be <8 months at the start of RSV season (typically from February/March through September).
• Tip: To determine who to reach out to, choose a start date in which it will be realistic to schedule those first appointments. This will help ensure patients will be < 8 months of age at time of administration. 
• High risk children who will be 8-19 months of age at the onset of the RSV season (October 2024).
• Evaluate eligibility and timing for any high-risk patient.

Testing 

The most common types of RSV clinical laboratory tests are: 

• Real-time reverse transcription-polymerase chain reaction (rRT-PCR), which is more sensitive than culture and antigen testing.
• Antigen testing, which is sensitive in children but less sensitive in adults.
• For infants and young children, both rRT-PCR and antigen detection tests are shown to be effective methods for diagnosing RSV infection. The sensitivity of RSV antigen detection tests is reported to generally range from 80% to 90% in this age group.
• Verify you have sufficient testing supplies and that all staff are trained in proper testing protocols.
• The TCCN McKesson Medical Supplies Program can help. Check with your McKesson representative or other supplier for needed supplies.

Coding 

• View the RSV CPT codes. 

Influenza (Flu) 

Vaccinations

• Flu is a trivalent vaccine this year.  
• All U.S. flu vaccines for this upcoming 2024-2025 season will be supplied in TIV formulation. More information from the CDC regarding the transition can be reviewed here.  
• Ensure your inventory of vaccines is well stocked and stored according to manufacturer guidelines. 
• Check-in with the vaccine manufacturer for shipping dates and pre-book orders.  
• Engaging with patients in conversations about the importance of the flu vaccine is crucial, especially for vulnerable populations like asthmatics. To support your recall efforts, TCCN securely emailed a list of asthmatic patients who are due for the flu vaccine to practices between September 4 to September 6. Practices should review these lists and their own files and contact patients appropriately. TCCN cannot guarantee that all patients will be reflected on its lists. 

Testing 

• Verify you have sufficient testing supplies and that all staff are trained in proper testing protocols. 
• The TCCN McKesson Medical Supplies Program can help. Check with your McKesson representative or other supplier for needed supplies. 

Coding 

• Because the flu vaccine is trivalent, CPT codes have changed. View the updated flu CPT codes here. Please update your systems according to the new codes.